Exact Mass: 353.28308300000003

Exact Mass Matches: 353.28308300000003

Found 109 metabolites which its exact mass value is equals to given mass value 353.28308300000003, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Isopropamide

(3-carbamoyl-3,3-diphenylpropyl)(methyl)bis(propan-2-yl)azanium

C23H33N2O+ (353.2592748)


Isopropamide is only found in individuals that have used or taken this drug. It is a long-acting quaternary anticholinergic drug. It is used in the treatment of peptic ulcer and other gastrointestinal disorders marked by hyperacidity and hypermotility.Anticholinergics are a class of medications that inhibit parasympathetic nerve impulses by selectively blocking the binding of the neurotransmitter acetylcholine to its receptor in nerve cells. The nerve fibers of the parasympathetic system are responsible for the involuntary movements of smooth muscles present in the gastrointestinal tract. Inhibition here decreases acidity and motility, aiding in the treatment of gastrointestinal disorders. A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AB - Synthetic anticholinergics, quaternary ammonium compounds C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent

   

Levomethadyl Acetate

(1S,4S)-4-(Dimethylamino)-1-ethyl-2,2-diphenylpentyl acetic acid

C23H31NO2 (353.2354666)


Levomethadyl Acetate is only found in individuals that have used or taken this drug. It is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. [PubChem]Opiate receptors (Mu, Kappa, Delta) are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Levomethadyl acetate effectively opens calcium-dependent inwardly rectifying potassium channels (OP1 receptor agonist), resulting in hyperpolarization and reduced neuronal excitability. N - Nervous system > N07 - Other nervous system drugs > N07B - Drugs used in addictive disorders > N07BC - Drugs used in opioid dependence D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics

   

Methadyl Acetate

(3R,6R)-3-Acetoxy-6-dimethylamino-4,4-diphenylheptane

C23H31NO2 (353.2354666)


Methadyl Acetate is only found in individuals that have used or taken this drug. It is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. [PubChem]Methadyl Acetate is primarily a mu-type opioid receptor agonist. It functions similarily to methadone. D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics

   

(3E,5E)-Trideca-3,5-dienoylcarnitine

3-(trideca-3,5-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C20H35NO4 (353.25659500000006)


(3E,5E)-Trideca-3,5-dienoylcarnitine is an acylcarnitine. More specifically, it is an (3E,5E)-trideca-3,5-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (3E,5E)-Trideca-3,5-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (3E,5E)-Trideca-3,5-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Palmitoyl Proline

1-hexadecanoylpyrrolidine-2-carboxylic acid

C21H39NO3 (353.29297840000004)


N-palmitoyl proline belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Palmitic acid amide of Proline. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Palmitoyl Proline is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Palmitoyl Proline is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

N-Oleoyl Alanine

2-[(1-Hydroxyoctadec-9-en-1-ylidene)amino]propanoate

C21H39NO3 (353.29297840000004)


N-oleoyl alanine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Oleic acid amide of Alanine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Oleoyl Alanine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Oleoyl Alanine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

Laurdan

1-[6-(dimethylamino)naphthalen-2-yl]dodecan-1-one

C24H35NO (353.27185000000003)


   

Proadifen

2-(Diethylamino)ethyl 2,2-diphenylpentanoic acid

C23H31NO2 (353.2354666)


   

Tetradecadienyl-l-carnitine

3-Hydroxy-3-[(trimethylazaniumyl)methyl]heptadeca-4,6-dienoic acid

C21H39NO3 (353.29297840000004)


   

22-oxo-docosanoate

Omega-ketodocosanoic acid(1-)

C22H41O3- (353.30555360000005)


22-oxo-docosanoate, also known as 22-oxobehenate or 22-oxo-c22:0(1-), is a member of the class of compounds known as very long-chain fatty acids. Very long-chain fatty acids are fatty acids with an aliphatic tail that contains at least 22 carbon atoms. 22-oxo-docosanoate is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 22-oxo-docosanoate can be found in a number of food items such as strawberry guava, fig, sea-buckthornberry, and rowal, which makes 22-oxo-docosanoate a potential biomarker for the consumption of these food products.

   
   

proadifen

proadifen

C23H31NO2 (353.2354666)


C471 - Enzyme Inhibitor > C29574 - Nitric Oxide Synthase Inhibitor D004791 - Enzyme Inhibitors

   
   

1-[1]Naphthyl-cyclohexancarbonsaeure-(2-diaethylamino-aethylester)|1-[1]naphthyl-cyclohexanecarboxylic acid-(2-diethylamino-ethyl ester)

1-[1]Naphthyl-cyclohexancarbonsaeure-(2-diaethylamino-aethylester)|1-[1]naphthyl-cyclohexanecarboxylic acid-(2-diethylamino-ethyl ester)

C23H31NO2 (353.2354666)


   

suaveolindole

suaveolindole

C23H31NO2 (353.2354666)


A terpenoid indole alkaloid that is 1H-indole substituted by cyclohexylmethyl ring at position 3 which in turn is substituted by additional methyl groups at positions 2 and 3, a propan-2-ylidene group at position 6 and a 2-carboxyethyl group at position 1. Isolated from Greenwayodendron suaveolens, it exhibits antibacterial activity.

   

methyl tumonoate A

methyl tumonoate A

C20H35NO4 (353.25659500000006)


A natural product found particularly in Oscillatoria margaritifera and Oscillatoria margaritifera.

   
   

(8,9-dihydroxy)-3-farnesylindole

(8,9-dihydroxy)-3-farnesylindole

C23H31NO2 (353.2354666)


   

1-methyl-2-[9?-oxo-(E)-7?-tridecenyl]-4(1H)-quinolone|euocarpine C

1-methyl-2-[9?-oxo-(E)-7?-tridecenyl]-4(1H)-quinolone|euocarpine C

C23H31NO2 (353.2354666)


   

1-methyl-2-[8?-oxo-(E)-9?-tridecenyl]-4(1H)-quinolone|euocarpine D

1-methyl-2-[8?-oxo-(E)-9?-tridecenyl]-4(1H)-quinolone|euocarpine D

C23H31NO2 (353.2354666)


   
   

1-methyl-2-[7-carbonyl-(E)-9-tridecenyl]-4(1H)-quinolone

1-methyl-2-[7-carbonyl-(E)-9-tridecenyl]-4(1H)-quinolone

C23H31NO2 (353.2354666)


   

1-Methyl-2-(Z)-8-tetradecenyl-4(1H)-quinolone

1-Methyl-2-(Z)-8-tetradecenyl-4(1H)-quinolone

C24H35NO (353.27185000000003)


   

2-amino-4,8-docosadiene-1,3-diol

2-amino-4,8-docosadiene-1,3-diol

C22H43NO2 (353.3293618)


   

(8α,9β-Dihydroxy)-3-farnesylindole

(8α,9β-Dihydroxy)-3-farnesylindole

C23H31NO2 (353.2354666)


   

Amorolfine hydrochloride

Amorolfine hydrochloride

C21H36ClNO (353.24852760000005)


D000890 - Anti-Infective Agents > D000935 - Antifungal Agents C254 - Anti-Infective Agent > C514 - Antifungal Agent

   

Oleoyl sarcosine

2-(N-Methyloleamido)acetic acid

C21H39NO3 (353.29297840000004)


   

Oleyl sarcosine

2-(N-Methyloleamido)acetic acid

C21H39NO3 (353.29297840000004)


CONFIDENCE standard compound; INTERNAL_ID 336; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6217; ORIGINAL_PRECURSOR_SCAN_NO 6216 CONFIDENCE standard compound; INTERNAL_ID 336; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6218; ORIGINAL_PRECURSOR_SCAN_NO 6216 CONFIDENCE standard compound; INTERNAL_ID 336; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6223; ORIGINAL_PRECURSOR_SCAN_NO 6221 CONFIDENCE standard compound; INTERNAL_ID 336; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6232; ORIGINAL_PRECURSOR_SCAN_NO 6231 CONFIDENCE standard compound; INTERNAL_ID 336; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6315; ORIGINAL_PRECURSOR_SCAN_NO 6314 CONFIDENCE standard compound; INTERNAL_ID 336; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 6201; ORIGINAL_PRECURSOR_SCAN_NO 6198 CONFIDENCE standard compound; INTERNAL_ID 336; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 11393; ORIGINAL_PRECURSOR_SCAN_NO 11388 CONFIDENCE standard compound; INTERNAL_ID 336; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 11413; ORIGINAL_PRECURSOR_SCAN_NO 11410 CONFIDENCE standard compound; INTERNAL_ID 336; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 11450; ORIGINAL_PRECURSOR_SCAN_NO 11448 CONFIDENCE standard compound; INTERNAL_ID 336; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 11464; ORIGINAL_PRECURSOR_SCAN_NO 11462 CONFIDENCE standard compound; INTERNAL_ID 336; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 11435; ORIGINAL_PRECURSOR_SCAN_NO 11433 CONFIDENCE standard compound; INTERNAL_ID 336; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 11483; ORIGINAL_PRECURSOR_SCAN_NO 11482

   
   

(8R)-9-((1S,Z)-1-hydroxy-1-methylhexahydro-2H-quinolizin-3(4H)-ylidene)-5,8-dimethylnonane-3,4-diol

(8R)-9-((1S,Z)-1-hydroxy-1-methylhexahydro-2H-quinolizin-3(4H)-ylidene)-5,8-dimethylnonane-3,4-diol

C21H39NO3 (353.29297840000004)


   

Anandamide (20:l, n-9)

(Z)-N-(2-hydroxyethyl)icos-11-enamide

C22H43NO2 (353.3293618)


   
   

N-oleoyl alanine

N-(9Z-octadecenoyl)-alanine

C21H39NO3 (353.29297840000004)


   

Methadyl acetate

Acetilmetadol [inn-spanish];Acetylmethadol;Acetylmethadolum [inn-latin];Betamethadol

C23H31NO2 (353.2354666)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics

   

NA 21:2;O2

N-(9Z-octadecenoyl)-alanine

C21H39NO3 (353.29297840000004)


   

3O-C16-HSL

N-(3-oxo-hexadecanoyl)-homoserine lactone

C20H35NO4 (353.25659500000006)


   

NAE 20:1

N-(11Z-eicosaenoyl)-ethanolamine

C22H43NO2 (353.3293618)


   

SPBP 16:0;O2

Hexadecaphinganine-1-phosphate

C16H36NO5P (353.2330976)


   

N-(2-aminoethyl)ethane-1,2-diamine,formaldehyde,4-nonylphenol

N-(2-aminoethyl)ethane-1,2-diamine,formaldehyde,4-nonylphenol

C20H39N3O2 (353.3042114)


   

Motretinide

2,4,6,8-Nonatetraenamide,N-ethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (2E,4E,6E,8E)-

C23H31NO2 (353.2354666)


D - Dermatologicals > D10 - Anti-acne preparations > D10A - Anti-acne preparations for topical use > D10AD - Retinoids for topical use in acne C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C804 - Retinoic Acid Agent C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids

   
   
   

3-(2-methoxy-5-methylphenyl)-3-phenyl-N,N-di(propan-2-yl)propanamide

3-(2-methoxy-5-methylphenyl)-3-phenyl-N,N-di(propan-2-yl)propanamide

C23H31NO2 (353.2354666)


   

1-[1-(4-Benzyloxyphenyl)-2-(dimethylamino)ethyl]cyclohexanol

1-[1-(4-Benzyloxyphenyl)-2-(dimethylamino)ethyl]cyclohexanol

C23H31NO2 (353.2354666)


   

tetradecyltrimethylammonium hydrogen sulfate

tetradecyltrimethylammonium hydrogen sulfate

C17H39NO4S (353.25996540000006)


   
   

Benzenemethanaminium,ar-dodecyl-N,N,N-trimethyl-, chloride (1:1)

Benzenemethanaminium,ar-dodecyl-N,N,N-trimethyl-, chloride (1:1)

C22H40ClN (353.2849110000001)


   
   

Betacetylmethadol

[(3S,6R)-6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate

C23H31NO2 (353.2354666)


C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist

   

benzyldimethyl(tridecyl)ammonium chloride

benzyldimethyl(tridecyl)ammonium chloride

C22H40ClN (353.2849110000001)


   

(carboxymethyl)dimethyloleylammonium hydroxide

(carboxymethyl)dimethyloleylammonium hydroxide

C22H43NO2 (353.3293618)


   

Laurdan

Laurdan

C24H35NO (353.27185000000003)


D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D049408 - Luminescent Agents D004396 - Coloring Agents > D005456 - Fluorescent Dyes

   

Alphacetylmethadol

(3R,6R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanyl acetate

C23H31NO2 (353.2354666)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics

   

Tridihexethyl Chloride

Tridihexethyl Chloride

C21H36ClNO (353.24852760000005)


C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent

   
   

Tetradecadienyl-l-carnitine

3-Hydroxy-3-[(trimethylazaniumyl)methyl]heptadeca-4,6-dienoic acid

C21H39NO3 (353.29297840000004)


   

2-[[(E)-octadec-9-enoyl]amino]propanoic acid

2-[[(E)-octadec-9-enoyl]amino]propanoic acid

C21H39NO3 (353.29297840000004)


   

(4E,6E)-3-hydroxy-3-[(trimethylazaniumyl)methyl]heptadeca-4,6-dienoate

(4E,6E)-3-hydroxy-3-[(trimethylazaniumyl)methyl]heptadeca-4,6-dienoate

C21H39NO3 (353.29297840000004)


   

(3E,5E)-Trideca-3,5-dienoylcarnitine

(3E,5E)-Trideca-3,5-dienoylcarnitine

C20H35NO4 (353.25659500000006)


   
   

4-[[(4S)-3-[2-(1-adamantyl)ethyl]-2-amino-4,5-dihydroimidazol-4-yl]methyl]phenol

4-[[(4S)-3-[2-(1-adamantyl)ethyl]-2-amino-4,5-dihydroimidazol-4-yl]methyl]phenol

C22H31N3O (353.2466996)


   

(8S,9S)-9-[(dimethylamino)methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

(8S,9S)-9-[(dimethylamino)methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

C17H31N5O3 (353.2426776)


   

(8R,9R)-9-[(dimethylamino)methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

(8R,9R)-9-[(dimethylamino)methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

C17H31N5O3 (353.2426776)


   

(8R,9R)-9-[(dimethylamino)methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

(8R,9R)-9-[(dimethylamino)methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

C17H31N5O3 (353.2426776)


   

(8S,9R)-9-[(dimethylamino)methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

(8S,9R)-9-[(dimethylamino)methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

C17H31N5O3 (353.2426776)


   

(8S,9R)-9-[(dimethylamino)methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

(8S,9R)-9-[(dimethylamino)methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

C17H31N5O3 (353.2426776)


   

(8R,9S)-9-[(dimethylamino)methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

(8R,9S)-9-[(dimethylamino)methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

C17H31N5O3 (353.2426776)


   

(8S,9S)-9-[(dimethylamino)methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

(8S,9S)-9-[(dimethylamino)methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

C17H31N5O3 (353.2426776)


   

(8S,9R)-9-[(dimethylamino)methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

(8S,9R)-9-[(dimethylamino)methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

C17H31N5O3 (353.2426776)


   

(8S,9R)-9-[(dimethylamino)methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

(8S,9R)-9-[(dimethylamino)methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

C17H31N5O3 (353.2426776)


   

(8R,9S)-9-[(dimethylamino)methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

(8R,9S)-9-[(dimethylamino)methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

C17H31N5O3 (353.2426776)


   

(8R,9S)-9-[(dimethylamino)methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

(8R,9S)-9-[(dimethylamino)methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

C17H31N5O3 (353.2426776)


   

(8R,9S)-9-[(dimethylamino)methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

(8R,9S)-9-[(dimethylamino)methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one

C17H31N5O3 (353.2426776)


   

(8S,9S)-9-[(dimethylamino)methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

(8S,9S)-9-[(dimethylamino)methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one

C17H31N5O3 (353.2426776)


   

2-Hydroxyerucate

2-Hydroxyerucate

C22H41O3- (353.30555360000005)


A 2-hydroxy fatty acid anion that is the conjugate base of 2-hydroxyerucic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

N-[(4E,8E)-1,3-dihydroxynonadeca-4,8-dien-2-yl]acetamide

N-[(4E,8E)-1,3-dihydroxynonadeca-4,8-dien-2-yl]acetamide

C21H39NO3 (353.29297840000004)


   

N-[(4E,8E)-1,3-dihydroxyoctadeca-4,8-dien-2-yl]propanamide

N-[(4E,8E)-1,3-dihydroxyoctadeca-4,8-dien-2-yl]propanamide

C21H39NO3 (353.29297840000004)


   

N-[(4E,8E)-1,3-dihydroxyheptadeca-4,8-dien-2-yl]butanamide

N-[(4E,8E)-1,3-dihydroxyheptadeca-4,8-dien-2-yl]butanamide

C21H39NO3 (353.29297840000004)


   

N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]heptanamide

N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]heptanamide

C21H39NO3 (353.29297840000004)


   

N-[(4E,8E)-1,3-dihydroxyhexadeca-4,8-dien-2-yl]pentanamide

N-[(4E,8E)-1,3-dihydroxyhexadeca-4,8-dien-2-yl]pentanamide

C21H39NO3 (353.29297840000004)


   

N-[(4E,8E)-1,3-dihydroxypentadeca-4,8-dien-2-yl]hexanamide

N-[(4E,8E)-1,3-dihydroxypentadeca-4,8-dien-2-yl]hexanamide

C21H39NO3 (353.29297840000004)


   

(Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]tridec-9-enamide

(Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]tridec-9-enamide

C21H39NO3 (353.29297840000004)


   

N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]nonanamide

N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]nonanamide

C21H39NO3 (353.29297840000004)


   

N-[(4E,8E)-1,3-dihydroxytrideca-4,8-dien-2-yl]octanamide

N-[(4E,8E)-1,3-dihydroxytrideca-4,8-dien-2-yl]octanamide

C21H39NO3 (353.29297840000004)


   

Monascaminone methyl ether

Monascaminone methyl ether

C23H31NO2 (353.2354666)


   

3-(1,2,2,6,6-Pentamethyl-1,2,3,6-tetrahydro-4-pyridinyl)-2-(2-methyl-2-aminopropyl)-1-methylindole

3-(1,2,2,6,6-Pentamethyl-1,2,3,6-tetrahydro-4-pyridinyl)-2-(2-methyl-2-aminopropyl)-1-methylindole

C23H35N3 (353.28308300000003)


   

Isopropamide

Isopropamide

C23H33N2O+ (353.2592748)


A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AB - Synthetic anticholinergics, quaternary ammonium compounds C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent

   

Levacetylmethadol

Levomethadyl Acetate

C23H31NO2 (353.2354666)


N - Nervous system > N07 - Other nervous system drugs > N07B - Drugs used in addictive disorders > N07BC - Drugs used in opioid dependence D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics

   

22-oxodocosanoate

22-oxodocosanoate

C22H41O3- (353.30555360000005)


An oxo fatty acid anion that is the conjugate base of 22-ketodocosanoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

N-gondoylethanolamine

N-gondoylethanolamine

C22H43NO2 (353.3293618)


A fatty amide obtained by the formal condensation of (11Z)-eicosaenoic acid with ethanolamine.

   
   

C16 Sphinganine-1-phosphate

C16 Sphinganine-1-phosphate

C16H36NO5P (353.2330976)


   

2-hydroxydocosenoate

2-hydroxydocosenoate

C22H41O3 (353.30555360000005)


A 2-hydroxy fatty acid anion with a chain that is composed of 22 carbons and 1 double bond (position unspecified).

   

AEA(20:1)

AEA(20:1)

C22H43NO2 (353.3293618)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

Sphingosine (d22:2)

SPH(d22:2)

C22H43NO2 (353.3293618)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   
   
   
   
   
   
   
   
   

C16 Sphinganine 1-phosphate

C16 Sphinganine 1-phosphate

C16H36NO5P (353.2330976)


   

15-ethylidene-12,16-dimethyl-6-(methylamino)-7-methylidenepentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-14-one

15-ethylidene-12,16-dimethyl-6-(methylamino)-7-methylidenepentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-14-one

C24H35NO (353.27185000000003)


   

12-(1h-indol-3-yl)-2,6,10-trimethyldodeca-2,6,10-triene-4,5-diol

12-(1h-indol-3-yl)-2,6,10-trimethyldodeca-2,6,10-triene-4,5-diol

C23H31NO2 (353.2354666)